Drugs / RBD5044
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05539651 | Nov 2022 → Oct 2024 | — | Suzhou Ribo Life Science Co. Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07587788 | Feb 2026 → Mar 2027 expected | hypertriglyceridemia | Ribotek Biopharmaceuticals (Shandong) Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06797401 | Jan 2025 → May 2026 overdue | hyperlipidemia | Ribocure Pharmaceuticals AB | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-08-31 | Suzhou Ribo Life Science Co. Ltd. | Results 瑞博生物在ESC 2026公布两项最新研究成果，进一步揭示甘油三酯、ApoC3、炎症与心血管健康之间的联系 ribolia.com ↗
RBD5044 的 I 期临床结果显示，可实现显著且持久的TG水平降低，并伴随脂质相关蛋白及炎症生物标志物的良性改变。 |
| 2026-08-31 | Ribocure Pharmaceuticals AB | Results Highlighting Triglycerides, APOC3 and Cardiovascular Health – New Data presented at ESC 2026 ribocure.com ↗
Meanwhile, our Phase 1 results for RBD5044, an APOC3-targeting siRNA, demonstrate that substantial and long-lasting triglyceride reduction is accompanied by favorable changes in lipid-related proteins and inflammatory biomarkers. |
| 2025-09-01 | Ribocure Pharmaceuticals AB | Results Ribo showcases new clinical data from its leading siRNA programs at ESC 2025, underscoring significant progress and achievements in advancing cardiovascular therapies ribocure.com ↗
Ribo presented results from its ApoC3-silencing RBD5044 program`s Phase 1 clinical trial, which included single and multiple ascending dose studies (n=72 healthy subjects). |
| 2024-10-29 | Ribocure Pharmaceuticals AB | Regulatory Ribo’s siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia ribocure.com ↗
On October 28, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the lipid-lowering siRNA drug RBD5044 that targets APOC3. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-31 | Suzhou Ribo Life Science Co. Ltd. | 瑞博生物在ESC 2026公布两项最新研究成果，进一步揭示甘油三酯、ApoC3、炎症与心血管健康之间的联系 ribolia.com ↗ |
| 2026-08-31 | Ribocure Pharmaceuticals AB | Highlighting Triglycerides, APOC3 and Cardiovascular Health – New Data presented at ESC 2026 ribocure.com ↗ |
| 2025-09-01 | Ribocure Pharmaceuticals AB | Ribo showcases new clinical data from its leading siRNA programs at ESC 2025, underscoring significant progress and achievements in advancing cardiovascular therapies ribocure.com ↗ |
| 2024-10-29 | Ribocure Pharmaceuticals AB | Ribo’s siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia ribocure.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBD5044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05539651 ↗ |
| Route | Subcutaneous | “subcutaneous injection of RBD5044” NCT05539651 ↗ |